Short term real-world Fingolimod efficacy and safety in Emirati patients with multiple sclerosis. (January 2020)

• Record Type: Journal Article
• Authors: Ceccarelli, Antonia; Mifsud, Victoria; Abusamra, Eslam; Hussain, Syed Irteza
• Is Part Of: Journal of clinical neuroscience. Volume 71(2020)
• Page Start: 39
• Page End: 42
• Publication Date: 2020-01
• Subjects: Fingolimod -- Real-world experience -- Multiple sclerosis -- Emirati -- Efficacy -- Safety; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2019.11.010
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: In the Middle East, few real world data of multiple sclerosis medications are available. This is the first real-world study assessing Fingolimod in Emirati multiple sclerosis patients. As early treatment, Fingolimod was safe and efficacious in limiting the disease in such population. Abstract: In clinical trials, Fingolimod was an efficacious and safe treatment for multiple sclerosis (MS). Despite this, few studies have explored its real-world efficacy and safety in the Middle East. The aim of this study was to describe our clinical experience with Fingolimod at Cleveland Clinic Abu Dhabi in Emirati patients with MS. We retrospectively collected clinical and brain and spinal cord MRI activity over time in 30 Emirati MS patients [F/M = 22/8, mean (SD) disease duration at treatment initiation = 3.3 (3.6) years, age at onset = 25.9 (6.9) years] who were commenced on Fingolimod from 2015 and followed for 18 months. The proportion of MS patients clinically and radiologically silent after Fingolimod initiation over time was assessed together with annualized relapse rate (ARR) reduction and adverse events (AEs) occurrence. 70% of MS patients who started Fingolimod were naïve. The baseline ARR [mean (SD; range)] was [1.2 (0.8; 0–4)] and 23.3% of MS patients had Gadolinium enhancing lesions at baseline MRI. Overall, the ARR was reduced by 72% and, relapses and MRI activity were found in only 24% and 38% of MS patients respectively. Mild to moderate AEs were observed in 33% of MS patients. No severe AEs were recorded. In Emirati MS patients, Fingolimod is safe and efficacious as an early treatment choice.